Navigation Links
FDA Approval of Ryanodex® Marks Milestone for Lyotropic Therapeutics
Date:8/6/2014

Richmond, Virginia (PRWEB) August 06, 2014

Lyotropic Therapeutics (Ashland, Virginia) today announced that its license partner, Eagle Pharmaceuticals, has received marketing approval by the U.S. Food and Drug Administration (FDA) for RYANODEX® (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. Ryanodex was developed and patented by Lyotropic Therapeutics and is licensed exclusively to Eagle Pharmaceuticals.

About Malignant Hyperthermia
MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. Once triggered, a rapidly progressing reaction involving sustained muscle contraction occurs with catastrophic consequences. Essential to the successful treatment of MH is the rapid institution of dantrolene sodium therapy and control of associated symptoms. Until now, dantrolene sodium preparation entailed a time-consuming reconstitution process and required several people for its preparation, a process that can take 15 to 20 minutes to mix, reconstitute and administer. Lyotropic Therapeutics developed Ryanodex to save critical time in preparation and administration of dantrolene sodium. Ryanodex can be prepared and administered in less than one minute by a single healthcare practitioner.

"Rapid administration of dantrolene sodium has long been recognized as key to reversal of MH. FDA approval of Ryanodex marks the availability of a major advance in the clinician’s ability to quickly prepare and deliver dantrolene sodium in the face of a fulminating MH crisis,” said Benjamin Cameransi, Jr., M.D., D.A.B.A., Vice President of Medical Affairs at Lyotropic Therapeutics. “In addition, approval of Ryanodex strongly validates the Company’s strategy of developing clinically significant new drugs backed with sound proof-of-concept data and then seeking a partner well positioned to complete product development and market the product.”

About Lyotropic Therapeutics
Lyotropic Therapeutics, Inc., based in Ashland, Virginia, is a pharmaceutical development company applying its substantial base of drug delivery technologies to develop unique, proprietary products with the goal of offering major therapeutic advances in patient safety and efficacy. The Company’s approach to product development and partnering has resulted in a significant portfolio of development stage injectable products in the field of anesthesia, pain management and critical care.

CONTACT:

for Lyotropic Therapeutics, Inc.

Vince Conklin, CEO
804.412.1030
vconklin(at)lyotropics(dot)com

Benjamin Cameransi, M.D. , D.A.B.A.,
Vice President of Medical Affairs
912.321.9112
bcameransi(at)lyotropics(dot)com
SOURCE Lyotropic Therapeutics, Inc.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12072145.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
2. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
3. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
6. CSafe Global Celebrates Six-Year Anniversary of RKN FAA Approval and Launch of Fleet
7. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
8. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
9. FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients
10. Humira and Simponi Have Been Prescribed By Significantly More U.S. Gastroenterologists in 2013 than in 2012, Likely Owing to Their Recent Approvals for Ulcerative Colitis
11. Profound Medical Receives IDE Approval from FDA to Conduct TULSA Clinical Trial for New Treatment for Localized Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... New Canaan, CT (PRWEB) , ... March 29, 2017 , ... ... of antibiotics and hormones in the world’s food supply through enhancement of the gut ... in the round included Connecticut Innovations , New York-based Sustainable Income Capital Management, ...
(Date:3/29/2017)... 2017 /PRNewswire/ - The University of Missouri Research Reactor ... of Sterigenics International, and General Atomics (GA), announce that ... the U.S. Nuclear Regulatory Commission (NRC). This marks a ... (Mo-99). Once operational, production from this facility will be ... Mo-99, which currently must be imported from outside ...
(Date:3/29/2017)... -- The Global Microfluidic Chips Market by Manufacturers, Countries, ... comprehensive study on the existing state of the global Microfluidic Chips ... Europe and Asia-Pacific , ... Africa . ... Browse 172 Tables and Figures, 13 Major Company Profiles, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Mass spectrometry is becoming more widely for clinical ... driven by its potential to perform challenging analyses in complex matrices and sample types. ... be addressed for it to be routinely used for medical testing. , ...
Breaking Biology Technology:
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
Breaking Biology News(10 mins):